O'Day Steven J

SEC source: 0001193125-26-339996 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-187083 · ownership.xml · derivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,333

Underlying: Common Stock · 95,333 shares

Expires 2036-04-24

F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

SEC source: 0001193125-26-187083 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0000950170-25-091630 · ownership.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,116

F1 · security: Reflects the executive's 2024 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 30-day lockup restriction with 100% of the award released on July 18, 2025.

F2 · price: $4.47 is the closing price of our Common Stock on June 18, 2025, the stock issuance date.

SEC source: 0000950170-24-127930 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-074837 · ownership.xml · derivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-01-16

F2 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 200,000 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074837 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,907

Underlying: Common Stock · 37,907 shares

Expires 2034-01-16

F1 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 758,140 Stock Options with an exercise price of $0.61.

SEC source: 0000899243-23-001320 · doc4.xml · derivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-01-05

F3 · derivative.exercise_date: Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

SEC source: 0000899243-23-001320 · doc4.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,384

F1 · security: Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.

F2 · price: $2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.

SEC source: 0000899243-22-004869 · doc4.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,003

F1 · security: Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary.

F2 · price: $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date.

SEC source: 0000899243-22-001245 · doc4.xml · nonDerivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,321

F2 · kind: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements related to the vesting. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.055 to $3.065. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-001245 · doc4.xml · derivative · entry 3

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On January 4, 2021, the reporting person was granted 100,000 restricted stock units that fully vested on January 4, 2022.

F3 · derivative.expiration_date: On January 4, 2021, the reporting person was granted 100,000 restricted stock units that fully vested on January 4, 2022.

SEC source: 0000899243-22-001245 · doc4.xml · nonDerivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000899243-22-000598 · doc4.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2022-01-02

F1 · derivative.exercise_date: One-third of the stock options vest on the one-year anniversary of the date of grant, with the remainder vesting in equal quarterly installments thereafter; provided that the Reporting Person maintains a service relationship with the Issuer through each such vesting date.